ContraFect’s Exebacase Receives the US FDA’s Breakthrough Therapy Designation for MRSA Bacteremia including Right-Sided Endocarditis

Shots:

• The BTD is based on P-II superiority trial assessing Exebacase + SOC antibiotic therapy vs SOC alone in patients with Staphylococcus aureus bacteremia, including endocarditis
• In a pre-specified analysis of the subgroup with MRSA infections, the clinical responder rate @day14 (74.1% vs 31.3%). The Exebacase demonstrated a reduction in the 30-day all-cause mortality, 4days reduction in length of hospital stay, and reductions in 30-day hospital readmission rates in MRSA-infected patients
• Exebacase is a recombinantly-produced lysin (cell wall hydrolase enzyme) with potent bactericidal activity against Staph aureus

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Exelixis